2025 Q4 -tulosraportti
23 päivää sitten
‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 000 | - | - | ||
| 153 | - | - | ||
| 27 286 | - | - | ||
| 1 720 | - | - | ||
| 3 031 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 1 260 051
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 1 260 051
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 t sittenIt must be difficult to redeem TO 14 as it looks today, most people probably think. So what could change that? A partner agreement, surely. One can fantasize that they have such a thing in the drawer but are waiting for the right timing to announce it to ensure that most people would immediately subscribe for TO 14. That applies to me regarding subscribing or not, in any case, and I am eagerly awaiting the next PM.
·7 t sittenHi Killroy. Do you know when we get the next PM? Thanks in advance.
·1 päivä sittenAlternatively - if you don't want to buy with your TO14, then hurry up and sell so others can buy. Even if it's only peanuts you get for them. Right now the buy side is large, and you get 0.004 SEK per unit. It is important that people who want to buy TO14 and put cash into the issue get the opportunity to do so. Because you cannot buy newly issued shares without having a corresponding number of TO.- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·1 päivä sitten · MuokattuI found out that the buy side for the stock was unfortunately "non-existent", and that I therefore would totally crash the ordinary share's current price by selling 650,000 ordinary shares. That would be directly counterproductive in relation to my call to use my standard technique to participate in the TO-issue - so I had to choose to sell my (expensively bought) TOs instead, so others could use them. I would have revised the text in the post, copied it, and deleted the original post. Unfortunately, the copying went awry and disappeared for me. If I get time, I'll have to rewrite it from scratch. Mvh BJN
- ·2 päivää sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.
·1 päivä sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined. 
·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?
2 päivää sitten · Muokattu2 päivää sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
23 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenIt must be difficult to redeem TO 14 as it looks today, most people probably think. So what could change that? A partner agreement, surely. One can fantasize that they have such a thing in the drawer but are waiting for the right timing to announce it to ensure that most people would immediately subscribe for TO 14. That applies to me regarding subscribing or not, in any case, and I am eagerly awaiting the next PM.·7 t sittenHi Killroy. Do you know when we get the next PM? Thanks in advance.
- ·1 päivä sittenAlternatively - if you don't want to buy with your TO14, then hurry up and sell so others can buy. Even if it's only peanuts you get for them. Right now the buy side is large, and you get 0.004 SEK per unit. It is important that people who want to buy TO14 and put cash into the issue get the opportunity to do so. Because you cannot buy newly issued shares without having a corresponding number of TO.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·1 päivä sitten · MuokattuI found out that the buy side for the stock was unfortunately "non-existent", and that I therefore would totally crash the ordinary share's current price by selling 650,000 ordinary shares. That would be directly counterproductive in relation to my call to use my standard technique to participate in the TO-issue - so I had to choose to sell my (expensively bought) TOs instead, so others could use them. I would have revised the text in the post, copied it, and deleted the original post. Unfortunately, the copying went awry and disappeared for me. If I get time, I'll have to rewrite it from scratch. Mvh BJN
- ·2 päivää sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.·1 päivä sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined.
- ·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?2 päivää sitten · Muokattu2 päivää sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 000 | - | - | ||
| 153 | - | - | ||
| 27 286 | - | - | ||
| 1 720 | - | - | ||
| 3 031 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 1 260 051
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 1 260 051
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
2025 Q4 -tulosraportti
23 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenIt must be difficult to redeem TO 14 as it looks today, most people probably think. So what could change that? A partner agreement, surely. One can fantasize that they have such a thing in the drawer but are waiting for the right timing to announce it to ensure that most people would immediately subscribe for TO 14. That applies to me regarding subscribing or not, in any case, and I am eagerly awaiting the next PM.·7 t sittenHi Killroy. Do you know when we get the next PM? Thanks in advance.
- ·1 päivä sittenAlternatively - if you don't want to buy with your TO14, then hurry up and sell so others can buy. Even if it's only peanuts you get for them. Right now the buy side is large, and you get 0.004 SEK per unit. It is important that people who want to buy TO14 and put cash into the issue get the opportunity to do so. Because you cannot buy newly issued shares without having a corresponding number of TO.
- 1 päivä sitten1 päivä sittenTämä julkaisu on poistettu.·1 päivä sitten · MuokattuI found out that the buy side for the stock was unfortunately "non-existent", and that I therefore would totally crash the ordinary share's current price by selling 650,000 ordinary shares. That would be directly counterproductive in relation to my call to use my standard technique to participate in the TO-issue - so I had to choose to sell my (expensively bought) TOs instead, so others could use them. I would have revised the text in the post, copied it, and deleted the original post. Unfortunately, the copying went awry and disappeared for me. If I get time, I'll have to rewrite it from scratch. Mvh BJN
- ·2 päivää sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.·1 päivä sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined.
- ·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?2 päivää sitten · Muokattu2 päivää sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 000 | - | - | ||
| 153 | - | - | ||
| 27 286 | - | - | ||
| 1 720 | - | - | ||
| 3 031 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 1 260 051
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 1 260 051
Välittäjätilasto
Dataa ei löytynyt